Arbutus Biopharma Corporation ABUS Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's stock issuance proceeds?
- Arbutus Biopharma Corporation (ABUS) reported stock issuance proceeds of $11.53M in Q1 2026.
- How has Arbutus Biopharma Corporation's stock issuance proceeds changed year-over-year?
- Arbutus Biopharma Corporation's stock issuance proceeds increased by 334.6% year-over-year, from $2.65M to $11.53M.
- What is the long-term trend for Arbutus Biopharma Corporation's stock issuance proceeds?
- Over 3 years (2021 to 2025), Arbutus Biopharma Corporation's stock issuance proceeds has grown at a -65.5% compound annual growth rate (CAGR), from $134.67M to $5.54M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.